In a single month, three reports describe different views of China's economic future
The director known for adding depth to the mundane will make the case that Gap's "Dress Normal" doesn't equal "dress boring"
Three times more money has been spent on the race for the state's school's chief than on the governor's race
An IT expert offers an estimate of what a 50-employee small business might spend to protect against cyberattacks
A slowdown in funding could end the growth of U.S. oil production
Independent developer Lucas Menge took it upon himself to adapt the smartwatch's home screen for the iPhone
Starbucks will start a coffee delivery program in late 2015, giving other companies' employees one fewer excuse to leave the office
New government rules could block 500 colleges from federal aid money and put hundreds more in danger of losing it
Candy sales are increasing, but big drugstores and supermarkets benefit more than local candy shops
Founders: Dr. Daniel J. Abrams; Tom Anchordoquy, PhD; and Karen Stevens, PhD
VC Investment over the last four quarters: $21.5 million
Founded in 2005, this seven-person biopharmaceutical company develops drugs for the treatment of severe central nervous system diseases. In addition to VC funding, Sierra received about $230,000 in grants from the State of Colorado, the University of Colorado, and the Coleman Institute. As for the recession, its founders say the company will be keeping close tabs on the funding and partnership environment over the next two to three years, despite already being funded for drug development work for the next three years.
Key to startup success: "Be persistent in the development of your data and business model to enable you to create a financial model that has a high likelihood of helping patients and therefore is fundable by the investor community."